Tenaya Therapeutics (TNYA) Total Non-Current Liabilities (2020 - 2026)

Tenaya Therapeutics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $28.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 17.28% year-over-year to $28.5 million; the trailing twelve-month figure through Mar 2026 stood at $28.5 million (up 17.28% YoY), and the FY2025 full-year result was $23.2 million, down 13.28% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $28.5 million, up from $23.2 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $35.3 million in Q4 2022, with the low at $21.8 million in Q3 2025.
• Average Total Non-Current Liabilities over 5 years is $28.1 million, with a median of $28.5 million recorded in 2026.
• Year-over-year, Total Non-Current Liabilities advanced 28.96% in 2022 and fell 23.83% in 2025.
• Tracing TNYA's Total Non-Current Liabilities over 5 years: stood at $35.3 million in 2022, then slipped by 12.74% to $30.8 million in 2023, then fell by 13.08% to $26.8 million in 2024, then fell by 13.28% to $23.2 million in 2025, then grew by 22.44% to $28.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $28.5 million (Q1 2026), $23.2 million (Q4 2025), and $21.8 million (Q3 2025), per Business Quant data.

Peer Comparison